BioSentinel Pharmaceuticals is a leading biotechnology company based in Madison, WI, specializing in the development of innovative tools and reagents for the study of botulinum neurotoxin (BoNT). Their cutting-edge tests and assays offer unparalleled speed, sensitivity, and accuracy, while also reducing testing costs and eliminating the need for animal usage. With a strong focus on research and development, BioSentinel provides a comprehensive suite of assays for the detection and quantification of BoNT in various samples, catering to the needs of both biodefense programs and pharmaceutical applications.
As a pioneer in the field, BioSentinel collaborates with renowned institutions such as the National Wildlife Health Center, the US Army Medical Research Institute of Chemical Defense, and the University of Wisconsin-Madison. Their team of experts is dedicated to designing rapid and sensitive detection technologies that meet the requirements of the US Department of Defense, the Department of Homeland Security, and pharmaceutical companies involved in FDA-approved cosmetic and therapeutic applications of BoNT. With a commitment to innovation and excellence, BioSentinel is at the forefront of advancing BoNT research and detection.
Generated from the website